DXCM vs IOVA
Dexcom vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
VS
IOVA
Iovance Biotherapeutics, Inc.
65
Buy
| Metric | DXCM | IOVA |
|---|
| AI Score |
65
|
65
|
| Price |
$89.16
|
$8.45
|
| P/E Ratio |
35.16×
|
-11.51×
|
| ROE |
30.5%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
62.5%
|
116.3%
|
| Debt / Equity |
0.53×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.4
|
67.0
|
| Beta |
1.41
|
0.701
|
| Expected Upside |
+2.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for DXCM versus IOVA.
The committee scores are tied.
DXCM and IOVA both score 65/100.
DXCM Committee View
67% agreement
6 analysts
The primary driver is eps growing 79.4% yoy. The main limiting factor is p/e of 34.5 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
IOVA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 97.8% signals elevated volatility — Risk